The Rise of Digital Dose Inhalers Market is Driven by Improving Access to Treatment

Digital dose inhalers are a class of handheld, portable devices that deliver medication to treat respiratory illnesses such as asthma and chronic obstructive pulmonary disease (COPD) through targeted inhalation. These electronic inhalers contain sensors that can track dose use, timing and other parameters to improve treatment adherence and clinical outcomes. The Global Digital Dose Inhaler Market is estimated to be valued at US$ 18.33 Bn in 2024 and is expected to exhibit a CAGR of 19% over the forecast period from 2024 to 2031.

Key Takeaways

Key players operating in the Digital Dose Inhaler Market Size  are 3M, AstraZeneca, GLENMARK PHARMACEUTICALS LTD., Novartis AG, Sensirion AG, Propeller Health, OPKO Health, Inc., Teva Pharmaceutical Industries Ltd., BEXIMCO Pharmaceuticals, GSK plc., Mundhipharma International, Honeywell International Inc., Veranex, Cognita Labs.

The growing prevalence of respiratory diseases such as asthma and COPD globally is expected to drive the demand for digital dose inhalers. As per the World Health Organization, over 300 million people worldwide suffer from asthma, while over 3 million die each year from COPD. Digital inhalers can help improve treatment adherence through remote monitoring capabilities.